Fenbufen

Identification

Name
Fenbufen
Accession Number
DB08981
Description

Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 254.2806
Monoisotopic: 254.094294314
Chemical Formula
C16H14O3
Synonyms
  • 3-(4-Biphenylylcarbonyl)propionic acid
  • 3-(4-Phenylbenzoyl)propionic acid
  • 4-(4-Biphenylyl)-4-oxobutyric acid
  • Fenbufen
  • Fenbufén
  • Fenbufène
  • Fenbufenum
  • gamma-oxo(1,1'-biphenyl)-4-butanoic acid
External IDs
  • CL 82,204
  • CL-82204

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirFenbufen may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Abciximab.
AcarboseFenbufen may decrease the excretion rate of Acarbose which could result in a higher serum level.
AcebutololFenbufen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fenbufen.
AcemetacinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Acenocoumarol.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Fenbufen.
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Fenbufen.
Acetylsalicylic acidThe risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Acetylsalicylic acid.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
M01AE05 — Fenbufen
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Biphenyls and derivatives / Butyrophenones / Gamma-keto acids and derivatives / Benzoyl derivatives / Aryl alkyl ketones / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Alkyl-phenylketone / Aromatic homomonocyclic compound / Aryl alkyl ketone / Benzenoid / Benzoyl / Biphenyl / Butyrophenone / Carboxylic acid / Carboxylic acid derivative / Gamma-keto acid
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
biphenyls, 4-oxo monocarboxylic acid (CHEBI:31599)

Chemical Identifiers

UNII
9815R1WR9B
CAS number
36330-85-5
InChI Key
ZPAKPRAICRBAOD-UHFFFAOYSA-N
InChI
InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
IUPAC Name
4-oxo-4-(4-phenylphenyl)butanoic acid
SMILES
OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1

References

Synthesis Reference

U.S. Patent 3,784,701.

General References
Not Available
KEGG Drug
D01344
PubChem Compound
3335
PubChem Substance
310264942
ChemSpider
3218
BindingDB
50240374
RxNav
24830
ChEBI
31599
ChEMBL
CHEMBL277522
ZINC
ZINC000000001427
PharmGKB
PA166049176
Wikipedia
Fenbufen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)185-187U.S. Patent 3,784,701.
Predicted Properties
PropertyValueSource
Water Solubility0.0121 mg/mLALOGPS
logP3.07ALOGPS
logP3ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)4.22ChemAxon
pKa (Strongest Basic)-7.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity72.49 m3·mol-1ChemAxon
Polarizability27.47 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f89-2900000000-b30afcea40626e90c194

Drug created on June 10, 2014 09:46 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates